| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 64.9 | 45.8 | 47.2 |
| Other income | 1.3 | 1.4 | 1.6 |
| Total income | 66.2 | 47.2 | 48.9 |
| Profit before exceptional items & tax | 10.5 | 7.3 | 7.3 |
| Exceptional items | 0.6 | 0.0 | 0.0 |
| Profit before tax | 9.9 | 7.3 | 7.3 |
| Net profit | 6.9 | 5.5 | 5.5 |
| Operating margin | 15.0% | 15.5% | 14.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +25.50% |
|---|---|
| Net profit, quarter on quarter | +25.50% |
| Revenue, year on year | +37.50% |
NSE results filing, NSE: NEOCHEM. Figures extracted from the filing.
Neochem Bio Solutions Ltd: key numbers
- Share price
- ₹106.20
- Market cap
- ₹181.8 Cr
- Revenue (annual)
- ₹110.7 Cr
- Net profit (annual)
- ₹12.03 Cr
- P/E (TTM)
- 15.1×Sector 37.5×
- Promoter holding
- 66.72%
- FII holding
- 0.18%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Neochem Bio Solutions Ltd
All →Neochem Bio Solutions Annual General Meeting
Neochem Bio Solutions Limited held its 9th Annual General Meeting on September 21, 2026, where management reviewed the company's performance and discussed future business strategies.
Neochem Bio Solutions Promoter Buying: ₹0.14 Cr
Promoter Swapnil R. Makati acquired 1,200 equity shares of Neochem Bio Solutions Limited for ₹0.14 Crore via an on-market purchase.
- Value
- ₹0.14 Cr
- Promoter stake change
- +0.01%
Neochem Bio Solutions Promoter Buying: ₹0.07 Cr
Promoter and MD Swapnil Makati purchased 7,200 Neochem Bio Solutions shares on NSE for ₹0.07 Crore. His stake rose from 54.70% to 54.74%.
- Value
- ₹0.07 Cr
- Promoter stake change
- +0.04%
Neochem Bio Solutions Earnings Call: Key Takeaways
Neochem Bio Solutions reported FY26 revenue of ₹110.7 Cr (+32% YoY) and PAT of ₹12.0 Cr (+62% YoY), driven by specialty chemical demand and segment diversification into home and personal care.
Neochem Bio Solutions Earnings Call: Key Takeaways
Neochem Bio Solutions delivered strong FY26 results with 32% revenue growth and 53% EBITDA growth, driven by a shift to own-brand performance chemicals and expansion into HPC and paints.
Neochem Bio Solutions Earnings Call: Key Takeaways
Neochem Bio Solutions delivered a strong FY26 with 32% revenue growth and 53% EBITDA expansion, driven by a strategic pivot from white-label manufacturing to its own higher-margin specialty brand.